ArticleMolecular medicine reports2018
Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis by mast cell suppression.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Potential Efficacy of Polyphenols and Isothiocyanates in the Management of Genitourinary Diseases: A Systematic Review of Preclinical and Clinical Studies.International journal of molecular sciences · 2026Pooled it
- Anti-Proliferative Effects of Resveratrol on Gingival Fibroblasts Derived From Amlodipine-Induced Gingival Overgrowth.Journal of periodontal research · 2026Article
- Resveratrol in benign prostatic hyperplasia: mechanistic insights and therapeutic perspectives.Frontiers in immunology · 2026Review
- Review
- Resveratrol inhibits calcium oxalate crystal growth, reduces adhesion to renal cells and induces crystal internalization into the cells, but promotes crystal aggregation.Current research in food science · 2024Article
- Polyphenol-based targeted therapy for oral submucous fibrosis.Inflammopharmacology · 2023Article
- Radial Extracorporeal Shock Wave Therapy Combined with Resveratrol Derivative Alleviates Chronic Nonbacterial Prostatitis in Rats.Inflammation · 2023Article
- Natural Polyphenols for Prevention and Treatment of Urinary Tract Infections.International journal of molecular sciences · 2023Review
- Screening of anti-chronic nonbacterial prostatitis activity of different extractions of the aerial part ofBiomedical reports · 2021Article
- Features of Remodeling of Prostate Stroma in Chronic Abacterial Prostatitis.Bulletin of experimental biology and medicine · 2021Article
- Resveratrol Modulates Transforming Growth Factor-Beta (TGF-β) Signaling Pathway for Disease Therapy: A New Insight into Its Pharmacological Activities.Biomedicines · 2020Review
- Resveratrol reduces inflammation-related Prostate Fibrosis.International journal of medical sciences · 2020Article
- Inflammatory mechanisms and oxidative stress in prostatitis: the possible role of antioxidant therapy.Research and reports in urology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Voiding dysfunction is the primary clinical manifestation of chronic prostatitis (CP), which is a common urological disease. The present study investigated whether prostate fibrosis was associated with urinary dysfunction in CP and if resveratrol improved urinary dysfunction, and the underlying molecular mechanism. A rat model of CP was established via subcutaneous injections of the pertussis‑diphtheria‑tetanus vaccine, which was followed by treatment with resveratrol. Bladder pressure and volume tests were performed to investigate the effect of resveratrol on urinary dysfunction in CP rats. Western blotting and immunohistochemical staining examined the expression levels of tryptase, chymase, transforming growth factor (TGF)‑β, Wnt and α‑smooth muscle actin (α‑SMA). The results demonstrated that the maximum capacity of the bladder, residual urine volume and maximum voiding pressure were increased significantly in the CP group compared with the control group. Mast cell (MC) activation, the activity of TGF‑β/Wnt/β‑catenin pathways, and the expression levels of tryptase and α‑SMA in the CP group were increased significantly compared with the control group. Resveratrol treatment significantly reversed these factors. Therefore, the results indicate that MC infiltration may induce prostate fibrosis, which exhibits a close association with urinary dysfunction in CP. Resveratrol may improve fibrosis via the suppression of MC activation and TGF‑β/Wnt/β‑catenin pathway activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.